Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
TuberculosisHIV
Interventions
DRUG

8 hourly LPV/r during TB treatment

8 hourly LPV/r during TB treatment

DRUG

Nevirapine

DRUG

Lopinavir/Ritonavir

Trial Locations (4)

7700

Red Cross Childrens Hospital, Cape Town

7725

KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town

Unknown

Queen Elizabeth Central Hospital, Blantyre

Desmond Tutu Centre, Cape Town

All Listed Sponsors
collaborator

Liverpool School of Tropical Medicine

OTHER

collaborator

Uppsala University

OTHER

collaborator

University of North Carolina

OTHER

lead

University of Cape Town

OTHER

NCT01637558 - Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) | Biotech Hunter | Biotech Hunter